Home Healthcare Pharmaceuticals Neurodegenerative Disease Market

Neurodegenerative Disease Market Size, Share & Trends Analysis Report By Disease Indication (Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, Others), By Drug Type (Immunomodulator, Vesicular Monoamine Transporter 2 (VMAT2), Others), By Routes of Administration (Oral, Intravenous (IV) delivery, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 04, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Neurodegenerative Disease Market, By Disease Indication 2022-2034 (USD MILLION/ Units)
    1. Multiple Sclerosis
    2. Parkinson's Disease
    3. Alzheimer's Disease
    4. Others
  2. Neurodegenerative Disease Market, By Drug Type 2022-2034 (USD MILLION/ Units)
    1. Immunomodulator
    2. Vesicular Monoamine Transporter 2 (VMAT2)
    3. Others
  3. Neurodegenerative Disease Market, By Routes of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Intravenous (IV) delivery
    3. Others
  4. Regional Neurodegenerative Disease Market
    1. North America
      1. North America Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      2. North America Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      3. North America Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
      4. U.S.
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      5. Canada
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
    2. Europe
      1. Europe Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      2. Europe Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      3. Europe Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
      4. U.K.
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      5. Germany
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      6. France
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      7. Spain
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      8. Italy
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      9. Russia
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      10. Nordic
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      11. Benelux
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      12. Rest of Europe
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
    3. APAC
      1. APAC Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      2. APAC Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      3. APAC Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
      4. China
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      5. Korea
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      6. Japan
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      7. India
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      8. Australia
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      9. Taiwan
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      10. South East Asia
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      11. Rest of Asia-Pacific
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
    4. Middle East and Africa
      1. Middle East and Africa Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      2. Middle East and Africa Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      3. Middle East and Africa Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
      4. UAE
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      5. Turkey
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      6. Saudi Arabia
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      7. South Africa
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      8. Egypt
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      9. Nigeria
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      10. Rest of MEA
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
    5. LATAM
      1. LATAM Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      2. LATAM Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      3. LATAM Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
      4. Brazil
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      5. Mexico
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      6. Argentina
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      7. Chile
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      8. Colombia
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      9. Rest of LATAM
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.